a's work is licensed to Caribou, which in turn has licensed use of its technology for human therapies to Intellia. The work of Doudna's co-inventor Emmanuelle Charpentier is licensed to CRISPR. And Doudna herself was an Editas co-founder but as MIT Technology Review first reported, later cut ties with the company. Whe